[/fullbar]
Explore This Issue
ACEP Now: Vol 40 – No 08 – August 2021References
- Milne K. And then there were none. ACEP Now. 2020;39(9):25.
- Guerrero WR, Savitz SI. Tissue-type plasminogen activator for stroke mimics: continuing to be swift rather than delaying treatment to be sure. Stroke. 2013;44(5):1213-1214.
- Ali-Ahmed F, Federspiel JJ, Liang L, et al. Intravenous tissue plasminogen activator in stroke mimics: findings from the get with the guidelines–stroke registry. Circ Cardiovasc Qual Outcomes. 2019;12(8):e005609.
- Zinkstok SM, Engelter ST, Gensicke H, et al. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke. 2013;44(4):1080-1084.
- Fee schedules–general information. Centers for Medicare & Medicaid Services website. Available. Accessed July 2, 2021.
- Pihlasviita S, Mattila OS, Ritvonen J, et al. Diagnosing cerebral ischemia with door-to-thrombolysis times below 20 minutes. Neurology. 2018;91(6):e498-e508.
- Liberman AL, Choi H-J, French DD, et al. Is the cost-effectiveness of stroke thrombolysis affected by proportion of stroke mimics? Stroke. 2019;50(2):463-468.
- Hsia AW, Luby ML, Leigh R, et al. Prevalence of imaging targets in patients with minor stroke selected for IV tPA treatment using MRI: the Treatment of Minor Stroke with MRI Evaluation Study (TIMES). Neurology. 2021;96(9):e1301-e1311.
- Goyal N, Male S, Al Wafai A, et al. Cost burden of stroke mimics and transient ischemic attack after intravenous tissue plasminogen activator treatment. J Stroke Cerebrovasc Dis. 2015;24(4):828-833.
Pages: 1 2 3 | Single Page
No Responses to “Thrombolysis in Stroke Mimics Is Not Harmless”